×
戻る Agenda
LS34: Impact of COVID-19 on US Clinical Studies Conducted by Japan-Based Pharmaceutical Companies
Session Chair(s)
Kazumi Taguchi, MSC
Discovery Accelerator,EIR Business Lead, Astellas Pharma, Japan
Speaker(s)
Yu Tanaka
Project Manager, Project Planning & Management Forum NY Chapter, United States
Takahiro Yoshida
Clinical Research Specialist, Study Operation, MSD, Japan